11:00pm (EST)
1. Market Summary
2. Best Buy (BBY) – Several Buy Signals
3. Affymax (AFFY) – This Biotech Baby Could Get Bigger
4. Earnings
5. Weekly Wrap Portfolio Update
6. Week Ahead
(To view the charts, please log into the Members Area and go to the Weekly Wrap Premium section)
= = = = = = = = = = = = = = =
1. Market Summary
The bulls’ came into the week feeling good about their chances in pushing the market past resistance. The bears’ only defense would be to hold the 200-day moving averages (MA’s) which came into play following Monday’s initial pop.
The indexes made a strong run at resistance to start the week after learning France and Germany had outlined the basic principles of another “plan” to solve Europe’s debt woes. However, the bulls’ momentum came to a screeching halt after rumors swirled that Standard & Poor’s was going to put several eurozone countries on “credit watch negative”. The market managed to recover from the headline blow to finish in positive territory which was the sign we were looking for.
Tuesday’s start felt like a hangover as Standard & Poor’s was back at it again saying they were considering expanding its downgrade threat against Europe to include the bailout fund which put some pressure on the market. U.S. futures were down 0.5% when the overseas markets starting trading but the bulls held support throughout the day and actually took the market fractionally higher.
Wednesday got off to a great start following word of a possible $600 billion International Monetary Fund (IMF) lending program which lead to a great open but the market finished flat for the day after an IMF official said no such action was being considered.
Thursday’s 2% drop was all about nervousness ahead of the European summit meeting on Friday and comments from ECB President Mario Draghi who said there would be no “QE” type of bond buying event, as rumored. This flushed out a lot of traders who basically threw in the towel and didn’t want to be long heading into Friday’s action.
Futures were steady before the European markets opened (3am EST) after 23 of the 27 EU leaders reached an agreement before their markets opened. Hungary, Sweden, and the Czech Republic will probably go along with the “plan for another new plan” to make it 26, but Britain has had enough and will go it alone. The relief rally on Friday was based on an agreement to loan the IMF $200 billion euro with $150 billion coming from the countries on board. They also gave themselves a 3-month extension to have a signed plan in place by March 2012 but we doubt Standard & Poor’s is satisfied.
The Dow jumped 186 points on Friday, or 1.6%, to settle at 12,184. The blue-chips traded to a high of 12,212 and we said resistance would come in at 12,200 if the 12,000 level and the 200-day MA (moving average) held. The bulls will push for 12,350-12,400 this week with a possible run to 12,600 if cleared. If the bears get hot and are able to take out 12,000, look for 11,800 to hold with further support at 11,600 and the 50-day MA. The Dow came into the week at 12,019 and added 165 points, or 1.4%. For the year, the blue-chips are showing a gain of 607 points, or 5.2%.
The S&P 500 advanced 21 points, or 1.7%, to end at 1,255. The index traded to a high of 1,258 on Friday and we were looking for a close above 1,250. The bulls struggled with the 200-day MA all week and we are looking for a surge past 1,275 for confirmation of a possible breakout and a run up to 1,300-1,325 by yearend. Short-term support held at 1,225-1,220 (50-day MA) and 1,200 will serve as backup. For the week, the index gained 11 points, or 0.9%, after starting Monday’s session at 1,244. For 2011, the S&P is down 2 points, or 0.2%.
The Nasdaq added 50 points, or 1.9%, to settle at 2,646. Tech traded to a high of 2,653 on Friday and we were looking for a close above 2,650 again. We mentioned last week resistance at 2,650-2,675 would be hard to clear without some clarity from Europe. If the bulls can get past the 200-day MA, then 2,700 would be a given with a possible shot at 2,800 by the end of the month. Support has been strong at 2,600 and further help is at 2,500 which would signal a trend reversal. The index started Monday at 2,627and popped 20 points, or 0.8%, for the week. YTD, the Nasaq is down 6 points, or 0.2%.
The S&P Volatility Index (^VIX, 26.38, down 4.21) came into the week under 30 and things were calm until Thursday’s market drop which caused the VIX to spike to a high of 30.91. The VIX settled above this level on the close but fell 14% on Friday’s rally. We covered last week’s “bearish triangle” which led to the drop below 30 and we said in October the VIX could come down to 22.50 by the time we close 2011. A break back above 30 and then 36 would be a trend change.
Friday’s action was good to see but the market is still vulnerable. Like we mentioned, Thursday’s action flushed out a lot of traders, as did the Thanksgiving pullback, so we could see them wanting to get back into the market. We have mentioned the flood of money still on the sidelines and Friday’s announcement at least bought Europe some more time. Maybe this will be enough to keep the headlines at bay until yearend and we can focus on the good news here at home.
Economic news has been improving, along with the jobless numbers, and housing is picking up in some areas. The FOMC meeting on Tuesday is the first hurdle the bulls will have to clear. If the Fed can sprinkle a new wrinkle in its policy statement then we could see a continued push higher.
The one thing that worries us is that some 4Q earnings announcements, which will start hitting the Street in January, could come in below the bar. We have already seen a few warnings but those that will miss and haven’t warned could see their share price take a hit. If there is a high profile miss or warning, it could signal trouble ahead.
= = = = = = = = = = = = = = =
Key of Technicals Used In Following Articles
2. Best Buy (BBY) – Several Buy Signals
Best Buy (BBY, $28.11, up 0.69) is getting a lot of chatter lately, such as early store openings, buyout speculation, a war with Amazon.com (AMZN, $193.03, up $2.55), and its upcoming earnings report. All these catalysts have caused some uncertainty in Best Buy’s stock which is down over 30% from its 52-week high of $42.57 so we wanted to cut through some of the clutter to see if there was a possible trade worth considering.
The company, for the first time ever, opened its stores early to Black Friday shoppers in an attempt to boost sales, which have been falling, partly due to Amazon’s strength and the recent momentum with its Fire tablet. Best Buy’s move proved worthwhile as retailers recorded a jump in traffic.
Amazon recently released an app which allows shoppers to scan bar codes on their iPhone or Android and compare the price with competitors. Dubbed Price Check, the app could possibly kill not only Best Buy but other retailers as consumers increasingly go for less expensive products and deals. The day Amazon launched a special $5 off deal on purchases through the app, people could have easily gone to Best Buy, swiped the bar code, purchased online, and left. Some of the retailers are smart and have “altered” how bar codes are being displayed because of this.
To help keep customers, Best Buy and other retailers have said they will match the price Amazon is selling items, but such a move will lower margins. To launch a counter offensive, Best Buy is substantially increasing the products available on its competing website, Best Buy Marketplace. The site allows third parties to sell their products at a fee, much like Amazon’s. Though it is still unknown how much market share Best Buy Marketplace can muster, the easiest way to eliminate this for Amazon would be to buy Best Buy which could make sense if it wants to take on Wal-Mart (WMT, $58.32, up $0.34) one day.
The chart below compares the BBY to AMZN, three of its competitors, and the industry.
Comparing BBY, the potential buyout target, to AMZN, the suitor, BBY appears a better value than AMZN in everything except revenue growth. Enterprise value/EBITDA is only 3.36, well in the range of buyout targets. Companies usually target acquisitions with a low enterprise value/EBITDA of about 5. However, investors seem to have more faith in AMZN, giving it a lower short interest. Since AMZN has no debt and $6.33 billion in cash, it will have to use most or all its cash and take on debt to buy BBY. A purchase could double AMZN’s revenue but it would be risky.
Comparing to its three other competitors, BBY appears a far better value than HGG and the only company listed that seems to match up to BBY’s numbers is AAPL. Both AAPL and WMT could buy BBY, but WMT already has a lot of debt. And we don’t think AAPL is interested in buying BBY, since it has its own stores.
There is also speculation that AMZN could use BBY stores to showcase its products, allowing customers to check out the product before buying it. AMZN started selling its Kindles at Best Buy and it would be easier if one could go to the local BBY whenever they needed customer service.
Tuesday will be a big day for the company as 3rd quarter (11/11) earnings could make or break the stock. Best Buy reports before the open, and at 10 am (EST), the company will hold a conference call.
Analysts predict earnings will come at $0.51 a share, down from $0.54 (or 6%) a share from a year ago and the $0.53 a share estimated three months ago. Revenue is expected to come in at $12.14 billion, up from $11.89 billion (or 2%) a year ago.
For the fiscal year, (2/12), analysts are looking for earnings and revenue of $2.17 a share on $17.28 billion, compared to $1.98 a share on $16.26 billion (up 6%) in sales. Estimates are included in the graphs below.
Clearly the 4th quarter (November – February) is the best quarter for the company in both earnings and revenue. Notice that 4th quarter earnings have been rising in a straight line for the past three years, indicating that the stores are still busy.
Analysts seem split on the stock, arguing Best Buy has been losing out to competition. At $28.11, the stock is just above its median target of $28 made by the 18 analysts recorded by Thomson/First Call. Mean target is $30, high target is $46 and low target is $21. Using a scale of 1.0 as a strong buy and 5.0 as a sell, the average rating of the stock was 2.5, unchanged from a week ago.
= = = = = = = = = = = = = = =
3. Affymax (AFFY) – This Biotech Baby Could Get Bigger
After the sweeping 15-1 vote by the FDA advisory panel for the approval of Affymax’s (AFFY, $7.64, down $0.34) drug Peginesatide, shares might have seen their lows.
This is big news for the $273 million biotech company as the next hurdle is getting FDA approval. Peginesatide (Hematide), is a treatment of anemia associated with chronic renal failure, is designed to stimulate production of red blood cells. Anemia is the reduction in the oxygen carrying capacity of blood, and since hemoglobin found in red blood cells carry oxygen, increasing red blood cells can help the situation. Renal failure, or kidney failure, can lead to anemia, since kidney failure can be linked to the secretion of the hormone erythropoietin, which stimulates the bone marrow to produce red blood cells. In addition, accumulation of uremic toxins and aluminum in the bone marrow can lead to anemia. An FDA approval would lead to the company’s first drug on the market.
Affymax has strategic alliance agreements with Takeda Pharmaceutical and Nektar Therapeutics to develop and commercialize Hematide. Under the agreement, Takeda and Affymax will share equal profits in the U.S, while Takeda will hold an exclusive license to develop and commercialize outside the U.S. Nektar supplies PEG (polyethylene glycol) to Affymax for the production of Hematide.
Despite the 15-1 recommendation, the FDA may or may not approve the drug. The advisory panel recommended approval of the drug despite Phase 3 results showing a higher rate of death and stroke in patients not on dialysis. Since safety has played a big role this year in FDA approvals, this could be a major setback for the company. Plus, the FDA has no obligation to follow the advisory panel’s recommendation as we seen with other drug stocks this year but they should hear something by the end of March.
The company was smart to only send application for approval only in patients on dialysis, where the cardiovascular risk wasn’t seen. So the FDA may actually approve the drug under this restriction.
Financially, Affymax looks sound. The company has no debt and $115.25 million in cash. Cash on hand is a little more than half its market cap. Current ratio is 7.15, meaning that it can cover current liabilities with current assets 7.15 times. Accounting standards say that if the current ratio is over two, a company is not in danger of not being able to cover its current liabilities, and short term credit is intact. Short interest is high at 10.70% of the float, which could cause a short squeeze, causing the shares to surge higher. However, the number of shares sold short compared to last month is slowly falling.
Amgen (AMGN, $58.59, up $0.18) currently dominates anemia therapy with Epogen, and if the FDA approves Hematide, this would be the first major threat to Amgen’s dominance. With Affymax’s sound financial position and its current market cap of only $300 million, it is possible that Amgen, or others, could make a bid for the company.
Amgen’s sales of Epogen reached $476 million in the 3rd quarter so Affymax is relatively cheap at $300 million. Assuming Hematide makes $100 million a quarter, almost 1/5 of Epogen’s sales, that is $400 million a year which makes the company clearly undervalued.
In comparing Hematide with Epogen, the FDA advisory panel found no significant differences. All anemia drugs, including Epogen, are erythropoiesis-stimulating agents, a class of drugs that have been linked to increased chances of heart trouble and death. Hematide only requires one dose a month, while Epogen requires a more frequent dosage.
At $7.64, the stock is near its low target of $7 made by the 6 analysts recorded by Thomson/First Call. Mean and median target is $10.50, and its high target is $13.00. Using a scale of 1.0 as a strong buy and 5.0 as a sell, the average rating of the stock was 1.9, unchanged from a week ago.
|
|
Current Month |
Last Month |
Two Months Ago |
Three Months Ago |
|
Strong Buy |
3 |
4 |
3 |
4 |
|
Buy |
4 |
3 |
3 |
2 |
|
Hold |
2 |
2 |
2 |
2 |
|
Underperform |
0 |
0 |
0 |
0 |
|
Sell |
0 |
0 |
0 |
0 |
= = = = = = = = = = = = = = =
4. Earnings
The companies in BOLD, we are looking at as possible trades and we may list call or put options on them in our Daily Newsletter. If they become official recommendations, we sent out Trade Alerts or include them in our 9am and 1pm updates that come out during the week (Quotes are as of Friday’s close, 12/9/11).
MONDAY
Aerosonic (AIM, $2.74, down $0.11), Biglari Holdings (BH, $357.50, up $8.62), BRT Realty Trust (BRT, $6.24, up $0.06), Cano Petroleum (CFW, $0.09, down $0.06), Daily Journal (DJCO, $63.68, Flat), Ditech Networks (DITC, $0.85, up $0.03), Elecsys (ESYS, $4.10, down $0.04), Forward Industries (FORD, $1.70, up $0.07), Frederick’s of Hollywood Group (FOH, $0.41, Flat), Frequency Electronics (FEIM, $7.88, up $0.11), Fuelcell Energy (FCEL, $0.95, up $0.05), General Steel Holdings (GSI, $1.15, down $0.01), IDT (IDT, $13.04, up $0.42), Innsuites Hospitality Trust (IHT, $2.10, up $0.01), NASB Financial (NASB, $9.59, up $0.12), Newlead Holdings (NEWL, $0.65, Flat), Schiff Nutrition International (WNI, $12.04, up $0.53), SigmaTron International (SGMA, $3.94, up $0.13), Uranium Energy (UEC, $3.16, up $0.13), Urstadt Biddle Properties (UBA, $17.23, up $0.61), Value Line (VALU, $11.60, down $0.51)
TUESDAY
ABM Industries (ABM, $21.03, up $0.41), Best Buy (BBY, $28.11, up $0.69), Diamond Foods (DMND, $40.56, up $14.01), FactSet Research Systems (FDS, $95.33, up $2.12), General Employment Enterprises (JOB, $0.33, down $0.01), Kingtone Wirelessinfo Solution Holding (KONE, $0.67, Flat), L & L Energy (LLEN, $2.91, up $0.06), Learning Tree International (LTRE, $6.80, up $0.49), Pantry (PTRY, $11.98, down $0.14), Rosetta Genomics (ROSG, $0.23, Flat)
WEDNESDAY
Alico (ALCO, $18.55, up $0.68), Apogee Enterprises (APOG, $11.26, up $0.59), Barnwell Industries (BRN, $3.18, up $0.02), CSP (CSPI, $3.42, up $0.04), Joy Global (JOYG, $89.65, Flat), MedCath (MDTH, $7.17, up $0.03), Medley Capital (MCC, $9.81, up $0.01), National Technical Systems (NTSC, $4.59, up 0.06), Nordson (NDSN, $47.32, up $1.08), Reading International (RDI, $4.27, Flat), Recon Technology (RCON, $0.50, up $0.02), Rick’s Cabaret International (RICK, $8.19, up $0.44), Synovis Life Technologies (SYNO, $18.72, up $0.84), Verifone Systems (PAY, $42.98, up $1.36)
THURSDAY
AAR (AIR, $4.85, up $0.08), Accenture (ACN, $58.71, up $2.04), Adobe Systems (ADBE, $28.04, up $0.66), Bioanalytical Systems (BASI, $1.50, up $0.04), Discover Financial Services (DFS, $24.74, up $0.77), Electro Sensors (ELSE, $4.20, Flat), Fedex (FDX, $83.24, up $0.90), Heico (HEI, $59.99, up $2.95), Hovnanian Enterprises (HOV, $1.58, up $0.09), Imperial Sugar (IPSU, $4.82, up $0.26), Nevada Gold and Casinos (UWN, $1.47, up $0.05), Nobility Homes (NOBH, $6.36, up $0.21), Overhill Farms (OFI, $3.91, up $0.01), Pier 1 Imports (PIR, $13.84, up $0.59), Pure Bioscience (PURE, $0.43, down $0.02), Quiksilver (ZQK, $3.18, up $0.13), Rentech (RTK, $1.55, down $0.03), Rite Aid (RAD, $1.25, up $0.06), Stewart Enterprises (STEI, $5.92, down $0.01), Triangle Petroleum (TPLM, $5.92, up $0.40), Tufco Technologies (TFCO, $3.09, down $0.06), Winnebago Industries (WGO, $6.92, up $0.35), WSP Holdings (WH, $0.44, down $0.05)
FRIDAY
Angeion (ANGN, $4.62, up $0.12), Darden Restaurants (DRI, $43.21, up $0.13), interCLICK (ICLK, $9.00, Flat)
= = = = = = = = = = = = = = =
5. Weekly Wrap Covered Call Portfolio Update (Closing prices as of 12/9/11)
WEEKLY WRAP CLOSED TRADES for 2011: SPRD +23%, CSCO +10%, VVUS, +17%, F + 7%, RMBS +16%, SYMC +4%, VVUS +18%, DNDN +9%, PCX +13%, SGEN +26%, TIVO +34%, REDF +11%, PCX +7%, GE +5%, CLNE +13%.
Note: The December options expire this Friday and there are a few trades that could get called-away (VVUS, SZYM, and NR). We will be looking for new candidates to replace them, or, we may recommend the same stocks again.
Clean Energy Fuels (CLNE, $12.67, up $0.29)
January 14 calls 2012 (CLNE120121C00014000, $0.45, flat)
Original Entry Price: $11.47 (11/23/11)
Lowered Price from Selling Options: $11.02
Exit Target: $15
Return: 15%
Stop Target: None
Action: Shares slipped 2% for the week but traded up to $13.40 on Monday. Resistance is will first come at the 200-day MA of $13.50 and then $14 which is our triggered strike price. Support is solid at $11.
We recommended buying the stock at $11.47 on 11/23/11 and for every 100 shares to sell the January 14 calls for 45 cents. This lowered the cost basis to $11.02.
If shares are called-away by mid-January at $14 the trade makes 27%.
Vivus (VVUS, $10.68, up $0.48)
December 10 calls (VVUS111217C00010000, $1.25, up $0.25)
Original Entry Price: $9.78 (11/23/11)
Lowered Price from Selling Options: $8.78
Exit Target: $12+
Return: 22%
Stop Target: None
Action: Vivus added 2% for the week and traded up to $10.79, twice, and $10.78 on Thursday. More importantly, shares held $10 all week and we will likely get called away this Friday. We may start another position if we are because we still want to be in Vivus. If shares can get past resistance at $11 then expect a run to $12+.
We recommended buying the stock at $9.78 on 11/23/11 and for every 100 shares to sell the December 10 calls for $1.00. This lowered the cost basis to $8.78.
If shares are called-away by mid-December at $10 the trade makes 14%.
Darling International (DAR, $13.98, up $0.47)
January 15 calls 2012 (DAR120117C00015000, $0.40, up $0.05)
Original Entry Price: $13.23 (11/23/11)
Lowered Price from Selling Options: $12.73
Exit Target: $15
Return: 10%
Stop Target: None
Action: Shares easily held support at $13 last week and traded to a high of $14.46 on Monday. Resistance is at $15 which is where we would get exercised.
We recommended buying the stock at $13.23 on 11/23/11 and for every 100 shares to sell the January 15 calls for 50 cents. This lowered the cost basis to $12.73.
If shares are called-away by mid-January at $15 the trade makes 18%.
Symantec (SYMC, $16.19, up $0.50)
January 17.50 calls 2012 (SYMC120121C00017500, $0.30, up $0.05)
Original Entry Price: $15.60 (11/23/11)
Lowered Price from Selling Options: $15.30
Exit Target: $18
Return: 6%
Stop Target: None
Action: Symantec traded down to $15.64 on Thursday’s pullback but easily held multi-year support at $15. Shares traded to a high of $16.73 last Monday and we expect a test to the $17-$18 range by mid-January.
We recommended buying the stock at $15.60 on 11/23/11 and for every 100 shares to sell the January 17.50 calls for 30 cents. This lowered the cost basis to $15.30.
If shares are called away by mid-January at $17.50 the trade makes 14%.
Solazyme (SZYM, $11.95, up $0.48)
December 12.50 calls (SZYM111217C00012500, $0.30, up $0.05)
Original Entry Price: $11.16 (11/14/11)
Lowered Price from Selling Options: $10.56
Exit Target: $15
Return: 13%
Stop Target: None
Action: Shares slipped 1% for the week but traded up to $13.34 until Thursday’s pullback. Resistance is at $14 while short-term support has moved up to $11 with backup at $10.50 and the 50-day MA.
We recommended buying the stock at $11.16 on 11/14/11 and for every 100 shares to sell the calls for 60 cents. This lowered the cost basis to $10.56.
If shares are called-away by mid-December at $12.50 the trade makes 18%.
Rambus (RMBS, $7.57, up $0.16)
December 20 calls (RMBS111217C00020000, $0.01, flat)
Original Entry Price: $17.83 (11/14/11)
Lowered Price from Selling Options: $16.38
Exit Target: $20+
Return: -54%
Stop Target: None
Action: Rambus is still struggling at the $8 level and $10 represents longer-term resistance. Support is at $6 if there is a continued pullback but a trading range between $7-$8 appears to be developing..
We recommended buying the stock at $17.83 on 11/14/11 and for every 100 shares to sell the calls for $1.45. This lowered the cost basis to $16.38.
If shares are called-away by mid-December at $20 the trade makes 22%.
Dendreon (DNDN, $7.96, down $0.05)
January 10 call 2012 (DNDN120121C00010000, $0.25, down $0.05)
Original Entry Price: $9.95 (10/26/11)
Lowered Price from Selling Options: $8.45
Exit Target: $12+
Return: -6%
Stop Target: None
Action: Dendeon is still flirting with support at $7.50 and has strong resistance up at $10. Shares were recently upgraded by one brokerage firm and tested $9 last Monday.
We recommended buying the stock at $9.95 on 10/26/11 and for every 100 shares to sell the November calls for $1. This lowered the cost basis to $8.85.
On 11/23/11 we recommended selling the January 10 call option for $0.50 which lowered the cost basis to $8.45.
If shares are called-away by mid-January at $10 the trade makes 18%.
MGM Resorts (MGM, $10.03, up $0.16)
January 11 call 2012 (MGM120121C00011000, $0.35, flat)
Original Entry Price: $11.73 (8/12/11)
Lowered Price from Selling Options: $9.28
Exit Target: $12+
Return: 8%
Stop Target: None
Action: Shares broke below $10 on Thursday which has been acting as both support and resistance. Further backup is at $9 but we are looking for a pop back to $11 by mid-January.
We recommended buying the stock at $11.73 on 8/12/11 and for every 100 shares to sell the September 12 calls for 90 cents. This lowered the cost basis to $10.83.
On 9/20/11 we recommended selling the October 12 call option for $0.60 which lowered the cost basis to $10.23.
On 10/26/11 we recommended selling the November 11 call option for $0.50 which lowered the cost basis to $9.73.
On 11/23/11 we recommended selling the January 11 call option for $0.45 which lowered the cost basis to $9.28.
If shares are called-away by mid-January at $11 the trade makes 19%.
Newpark Resources (NR, $9.32, up $0.34)
December 10 call (NR111217C00010000, $0.20, flat)
Original Entry Price: $9.45 (7/27/11)
Lowered Price from Selling Options: $8.10
Exit Target: $10+
Return: 15%
Stop Target: None
Action: Newpark slipped below $9 before closing above this level on Friday. There is strong support at $8 and resistance has been strong at $9.50. If shares stay below $10 we will look to write a January or February call.
We recommended buying the stock at $9.45 on 7/27/11 and for every 100 shares to sell the August 10 calls for 50 cents. This lowered the cost basis to $8.95.
On 9/15/11 we recommended selling the December 10 call option for $0.85 which lowered the cost basis to $8.10.
If we are called away at $10 in mid-December, the trade makes 23%.
Rare Element Resources (REE, $4.89, down $0.03)
Original Entry Price: $12.38 (5/31/11)
Lowered Price from Selling Options: $11.23
Exit Target: $15+
Return: -56%
Stop Target: None
Action: Support is at $4 with $6 becoming short-term resistance as shares seem to be settling in a range.
We recommended buying the stock at $12.38 on 5/31/11 and for every 100 shares to sell the July 12 calls for $1.15. This lowered the cost basis to $11.23.
AKS Steel Holding (AKS, $8.61, up $0.23)
Original Entry Price: $15.93 (5/2/11)
Lowered Price from Selling Options (and dividends): $14.43
Exit Target: $20+
Return: -40%
Stop Target: None
Action: Shares held $8 which is home of its 50-day MA and made a run at $9 which would be bullish if cleared. There is support at $7 if shares retreat.
We recommended buying the stock at $15.93 on 5/2/11 and for every 100 shares to sell the May 16 calls for 50 cents. This lowered the cost basis to $15.43.
On 5/11/11 the company paid out a 5 cent quarterly dividend. This lowered the cost basis to $15.38.
On 7/1/11 we recommended selling the August 16 call option for $0.85 which lowered the cost basis to $14.53.
On 8/11/11 the company paid out a 5 cent quarterly dividend. This lowered the cost basis to $14.48.
On 11/10/11 the company paid out a 5 cent quarterly dividend. This lowered the cost basis to $14.43.
American Capital (ACAS, $7.08, up $0.24)
Original Entry Price: $9.73 (4/19/11)
Lowered Price from Selling Options: $8.38
Exit Target: $15+
Return: -16%
Stop Target: None
Action: American Capital traded below $7 for much of the week and support is strong at $6.50. Resistance has been tough to clear at $7.50 but we will be able to write call another call option at $8 if cleared.
We recommended buying the stock at $9.73 on 4/19/11 and for every 100 shares to sell the June 10 call for 50 cents. This lowered the cost basis to $9.23.
On 7/1/11 we recommended selling the August 10 call option for $0.55 which lowered the cost basis to $8.68.
On 9/13/11 we recommended selling the October 9 call option for $0.30 which lowered the cost basis to $8.38.
DryShips (DRYS, $2.37, up $0.03)
January 2012 7.50 call (DRYS120121C00007500, $0.01, flat)
Entry Price: $5.25 (1/03/11)
Lowered Price from Selling Options: $4.60
Exit Target: $8
Return: -48%
Stop Target: None
Action: DryShips continues to test support at $2.00 while battling resistance at $2.50.
DryShips opened at $5.37 on 1/3/11 and shares were at $5.25 shortly after the bell. The January call options could have been sold for 65 cents which lowered the cost basis to $4.60.
If shares are over $7.50 by January 2012, the stock will be “called away” and the trade will make over 60%.
= = = = = = = = = = = = = = =
6. Week Ahead
Economic news is light to start the week as the Treasury Budget will be the only noteworthy headline on Monday.
On Tuesday, Retail Sales are due before the bell followed by Business Inventories 30 minutes after the open. Later in the day, the market will get the latest FOMC Rate Decision.
For Wednesday, the MBA Mortgage Index is due out at 7am (EST) followed by Import/ Export Prices an hour before the session starts. Crude Inventories will be released 60 minutes after the start of trading.
Thursday’s news will center on Initial Claims and Continuing Claims followed by the Producer Price Index (PPI) and Empire Manufacturing numbers, all before the open. If that weren’t enough, Industrial Production and Capacity Utilization will also hit Wall Street before the bell. The Philly Fed report is due out at 10am and will carry weight.
The market will end the week with Friday’s Consumer Price Index (CPI) report.
Rick Rouse
Chief Options Strategist
Rick@MomentumOptionsTrading.com
“What Are You Doing TODAY to become a millionaire TOMORROW?”
Member Area:
https://MomentumOptionsTrading.com/amember/login.php
Momentum Options Trading, LLC
10908 Courthouse Rd., Suite 102-231
Fredericksburg, VA 22408
(888) 898–0837
======================
All communications are for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy securities, currencies including spot, futures and/or options or any other financial instrument.
Any issue or recommendation contained herein may not be suitable for all investors. Moreover, any issue offered herein is not guaranteed or endorsed by Momentum Options Trading LLC, not FDIC insured and may lose value.
IMPORTANT NOTICE: Risk Disclosure
Unique experiences and past performances do not guarantee future results! Testimonials herein are unsolicited and received no compensation; certain accounts may have worse performance than that indicated. Trading stocks, futures, options and spot currencies involves substantial risk and there is always the potential for loss. Your trading results may vary. Because the risk factor is high in the foreign exchange market trading, only genuine “risk” funds should be used in such trading. If you do not have the extra capital that you can afford to lose, you should not trade in the foreign exchange market. No “safe” trading system has ever been devised, and no one can guarantee profits or freedom from loss.
U.S. Government Required Disclaimer – Commodity Futures Trading Commission. Forex, Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don’t trade with money you can’t afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results.
HYPOTHETICAL PERFORMANCE RESULTS HAVE MANY INHERENT LIMITATIONS, SOME OF WHICH ARE DESCRIBED BELOW. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN. IN FACT, THERE ARE FREQUENTLY SHARP DIFFERENCES BETWEEN HYPOTHETICAL PERFORMANCE RESULTS AND THE ACTUAL RESULTS SUBSEQUENTLY ACHIEVED BY ANY PARTICULAR TRADING PROGRAM ONE OF THE LIMITATIONS OF HYPOTHETICAL PERFORMANCE RESULTS IS THAT THEY ARE GENERALLY PREPARED WITH THE BENEFIT OF HINDSIGHT. IN ADDITION, HYPOTHETICAL TRADING DOES NOT INVOLVE FINANCIAL RISK, AND NO HYPOTHETICAL TRADING RECORD CAN COMPLETELY ACCOUNT FOR THE IMPACT OF FINANCIAL RISK IN ACTUAL TRADING. FOR EXAMPLE, THE ABILITY TO WITHSTAND LOSSES OR ADHERE TO A PARTICULAR TRADING PROGRAM IN SPITE OF TRADING LOSSES ARE MATERIAL POINTS WHICH CAN ALSO ADVERSELY AFFECT ACTUAL TRADING RESULTS. THERE ARE NUMEROUS OTHER FACTORS RELATED TO THE MARKETS IN GENERAL OR TO THE IMPLEMENTATION OF ANY SPECIFIC TRADING PROGRAM WHICH CANNOT BE FULLY ACCOUNTED FOR IN THE PREPARATION OF HYPOTHETICAL PERFORMANCE RESULTS AND ALL OF WHICH CAN ADVERSELY AFFECT ACTUAL TRADING RESULTS.
Substantial risk is involved. Trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the markets. Don’t trade with money you can’t afford to lose. Nothing in our course or website shall be deemed a solicitation or an offer to Buy/sell futures and/or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on our site. Also, the past performance of any trading methodology is not necessarily indicative of futures results. Trading involves high risks and you can lose a lot of money.




















